Bacteriophage Bioengineering: A Transformative Approach for Targeted Drug Discovery and Beyond
Open Access
Abstract
Bacteriophages, the viruses that infect and replicate within bacteria, have long been recognized as potential therapeutic agents against bacterial infectionsKeywords
Funding Information
- AMED (JP21gm1610002, JP22ae0121045, JPJ009237)
- Cabinet Office, Government of Japan (JP21gm1610002, JP22ae0121045, JPJ009237)
This publication has 21 references indexed in Scilit:
- Engineering therapeutic phages for enhanced antibacterial efficacyCurrent Opinion in Virology, 2022
- Engineered Bacteriophage Therapeutics: Rationale, Challenges and FutureBioDrugs, 2021
- Phage-Encoded EndolysinsAntibiotics, 2021
- Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteriaNature Communications, 2020
- Endolysins as emerging alternative therapeutic agents to counter drug-resistant infectionsInternational Journal of Antimicrobial Agents, 2020
- Phage-Guided Targeting, Discriminative Imaging, and Synergistic Killing of Bacteria by AIE BioconjugatesJournal of the American Chemical Society, 2020
- Engineering Bacteriophages as Versatile BiologicsTrends in Microbiology, 2019
- Phage Therapy in the Postantibiotic EraClinical Microbiology Reviews, 2019
- Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteriaProceedings of the National Academy of Sciences, 2015
- Bacteriophage resistance mechanismsNature Reviews Microbiology, 2010